Press Release Oct 26 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Micafungin for Injection. This medication is used to treat various fungal infections and to prevent such infections in patients undergoing stem cell transplants. The drug will be produced at the company's manufacturing facility in Jarod, near Vadodara, India. The press release highlights that Micafungin had significant annual sales in the United States according to market data.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 22 2022
- Press Release Oct 17 2022
- Zydus Lifesciences: General updates
- Press Release Oct 06 2022
- Press Release Oct 04 2022
Later from Zydus Lifesciences
- Press Release Oct 29 2022
- Press Release Nov 03 2022
- Press Release Nov 07 2022
- Press Release Nov 08 2022
- Press Release Nov 16 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences